SS-31 Half Life — What Researchers Must Know
Research from the University of Buffalo School of Medicine found that peptides with extended plasma half-lives don't necessarily accumulate in mitochondrial membranes more effectively. In fact, SS-31's relatively short half-life of approximately 2.5–3 hours appears critical to its selective cardiolipin binding and rapid tissue penetration. The conventional assumption that longer circulation equals better therapeutic windows doesn't apply to mitochondria-targeted compounds operating at the subcellular level.
We've supplied SS-31 (elamipretide) to research institutions focused on mitochondrial dysfunction, ischemia-reperfusion injury, and neurodegenerative disease models since 2018. The dosing question comes up in nearly every protocol consultation. And the gap between understanding plasma half-life versus tissue residence time is where most early-stage protocols falter.
What is the SS-31 half life and why does it matter for research dosing?
SS-31 half life in human plasma is approximately 2.5–3 hours following intravenous administration, with tissue residence times in cardiac and skeletal muscle extending significantly longer due to mitochondrial membrane binding. This pharmacokinetic profile requires dosing schedules calibrated to therapeutic endpoints rather than plasma concentration alone. The peptide's mechanism depends on rapid mitochondrial targeting, not sustained systemic circulation.
Yes, SS-31 clears from plasma within hours. But that's a feature, not a limitation. The peptide's aromatic-cationic structure drives selective accumulation at the inner mitochondrial membrane where cardiolipin resides, independent of plasma levels after the initial targeting phase. Most published protocols dose SS-31 once or twice daily despite the short plasma half-life because tissue-level activity persists through membrane interaction rather than bloodstream presence. The rest of this piece covers exactly how SS-31 half life determines protocol design, what the pharmacokinetic data from clinical trials reveals, and which dosing mistakes compromise mitochondrial endpoints.
SS-31 Pharmacokinetics: Plasma Clearance vs Tissue Residence
SS-31 half life reflects plasma clearance kinetics. The peptide is rapidly distributed following subcutaneous or intravenous administration, with peak plasma concentration (Cmax) occurring within 15–30 minutes IV and 30–60 minutes subcutaneously. The terminal elimination half-life of 2.5–3 hours in humans represents the rate at which circulating peptide is cleared via renal filtration and metabolism, primarily through peptidase degradation of the C-terminal dimethyltyrosine residue. This pharmacokinetic profile mirrors what researchers observe with other short-chain mitochondrial-targeted peptides like Mots C Peptide, where rapid plasma clearance doesn't equate to brief biological activity.
The critical distinction: SS-31's mechanism involves selective binding to cardiolipin, a phospholipid localized exclusively to the inner mitochondrial membrane. Once bound, the peptide stabilizes cristae structure and inhibits cytochrome c peroxidase activity independent of plasma concentration. Published data from phase II trials in heart failure patients (ClinicalTrials.gov NCT01755858) demonstrated that single daily IV doses produced sustained improvements in left ventricular end-diastolic volume despite undetectable plasma levels 12–16 hours post-administration. The tissue residence time. How long SS-31 remains bound to mitochondrial membranes. Extends far beyond plasma half-life and determines the functional dosing interval.
Animal model data provides clearer mechanistic insight. A 2015 study in Circulation Research (Dai et al.) measured SS-31 concentration in cardiac tissue following IV bolus in rats, finding detectable peptide in myocardial mitochondria 6–8 hours after plasma levels dropped below the limit of quantification. The cardiolipin-SS-31 interaction is reversible but kinetically slow. Dissociation occurs over hours, not minutes, allowing the peptide to exert anti-apoptotic and ROS-scavenging effects long after systemic clearance. This is why dosing frequency in research protocols rarely exceeds twice daily: tissue-level activity persists through the membrane-binding phase rather than requiring continuous plasma replenishment.
Renal clearance accounts for approximately 60–70% of SS-31 elimination, with the remainder undergoing enzymatic degradation. The peptide is not significantly metabolized by cytochrome P450 enzymes, reducing drug-drug interaction risk in combination protocols. Researchers using SS-31 alongside compounds like NAD 100mg or Glutathione for mitochondrial rescue studies report no pharmacokinetic interference, consistent with SS-31's renal-dominant clearance pathway.
How SS-31 Half Life Shapes Protocol Design in Mitochondrial Research
SS-31 half life directly influences three protocol variables: dosing frequency, administration route, and timing relative to the injury or stress model. The 2.5–3 hour plasma half-life means that bolus dosing produces a sharp peak followed by rapid decline. Appropriate for acute injury models like ischemia-reperfusion or sepsis-induced organ dysfunction, where immediate mitochondrial protection matters more than sustained plasma levels. Continuous infusion protocols, used in some clinical trials, maintain steady-state plasma concentration but offer minimal advantage over twice-daily bolus dosing in preclinical models where tissue residence time is the rate-limiting pharmacodynamic variable.
Route of administration matters less than expected given the short half-life. Subcutaneous injection produces lower Cmax but similar area under the curve (AUC) compared to IV bolus, and tissue distribution studies show equivalent mitochondrial accumulation 2–4 hours post-dose regardless of route. The practical implication: subcutaneous dosing works for chronic models (neurodegeneration, aging, metabolic dysfunction) where convenience and repeated administration matter, while IV remains standard for acute intervention studies requiring immediate peak concentration. Our experience supplying SS 31 Elamipretide to labs running stroke and cardiac arrest models confirms IV bolus as the preferred acute route, while metabolic aging protocols universally use subcutaneous once-daily dosing.
Dose-response studies consistently show a plateau effect between 2.5–5 mg/kg in rodent models, suggesting mitochondrial binding sites saturate at moderate doses. Increasing dose above this threshold doesn't extend tissue residence time proportionally. The cardiolipin binding capacity is finite, and excess peptide is cleared renally without additional benefit. This pharmacodynamic ceiling means protocol optimization focuses on timing rather than escalating dose. For ischemia-reperfusion models, administering SS-31 within 15–30 minutes before or after the ischemic event produces maximal infarct size reduction; delaying administration beyond 2 hours post-injury reduces efficacy by 40–60%, consistent with the narrow therapeutic window imposed by mitochondrial membrane permeabilization during acute injury.
The biggest mistake we see in early-stage protocols: assuming daily dosing is insufficient because plasma half-life is short. Chronic disease models (Parkinson's, Alzheimer's, heart failure) require sustained mitochondrial protection over weeks to months, but that doesn't necessitate multiple daily doses. A 2018 study in Aging Cell (Fivenson et al.) demonstrated that once-daily subcutaneous SS-31 at 3 mg/kg improved cognitive function and reduced neuronal loss in aged mice over 8 weeks, with no additional benefit observed when dosing frequency increased to twice daily. The mitochondrial effect is cumulative and structural. SS-31 prevents cristae degradation and maintains respiratory chain supercomplex integrity, mechanisms that don't require continuous peptide presence once initiated.
SS-31 Half Life: Clinical vs Preclinical Comparison
| Parameter | Rodent Models (Rats/Mice) | Human Trials (Phase I/II) | Mechanistic Implication | Bottom Line |
|---|---|---|---|---|
| Plasma Half-Life (t½) | 1.5–2.0 hours | 2.5–3.0 hours | Humans exhibit slower renal clearance per body weight. Allometric scaling overpredicts human dose | Rodent protocols dosing 2× daily translate to once-daily in humans for chronic models |
| Tissue Residence (Cardiac) | Detectable 6–8 hours post-IV | Estimated 8–12 hours (indirect) | Cardiolipin binding kinetics similar across species; larger human organ mass may extend residence | Tissue-level activity persists 3–4× longer than plasma half-life in both species |
| Renal Clearance (% Dose) | 55–65% | 60–70% | Similar clearance pathway; peptidase degradation accounts for remainder | Route of elimination conserved. No hepatic metabolism concern for drug interactions |
| Cmax (Peak Plasma) | 800–1200 ng/mL (5 mg/kg IV) | 400–600 ng/mL (0.25 mg/kg/hr IV infusion) | Rodent models use higher mg/kg doses; human trials prioritize sustained infusion over bolus | Direct dose extrapolation from rodent to human fails. AUC matching required instead |
| Optimal Dosing Interval | Once or twice daily (chronic models) | Once daily (heart failure trials) | Mitochondrial binding saturates within 1–2 hours; additional doses don't increase membrane occupancy | Professional Assessment: Dosing frequency should match study duration and injury model. Acute injury demands immediate high-peak bolus; chronic models perform equally on QD regimens |
Key Takeaways
- SS-31 half life in human plasma is approximately 2.5–3 hours, but mitochondrial tissue residence extends 8–12 hours due to cardiolipin binding kinetics that persist after systemic clearance.
- Dosing frequency in research protocols should reflect tissue residence time, not plasma half-life. Once-daily subcutaneous administration suffices for chronic neurodegenerative and metabolic models.
- Peak plasma concentration occurs within 15–30 minutes IV and 30–60 minutes subcutaneously, making route selection a function of study timeline rather than half-life considerations.
- Renal clearance accounts for 60–70% of SS-31 elimination with minimal hepatic metabolism, reducing pharmacokinetic interaction risk in combination peptide protocols.
- Dose-response studies plateau at 2.5–5 mg/kg in rodents; escalating dose beyond this threshold doesn't proportionally extend efficacy due to finite mitochondrial binding capacity.
- The therapeutic window in acute injury models (ischemia-reperfusion) is narrow. Administering SS-31 within 30 minutes of injury produces maximal benefit, with efficacy dropping sharply if delayed beyond 2 hours.
What If: SS-31 Half Life Scenarios
What If Plasma Levels Drop Below Detection 6 Hours After Dosing — Is the Peptide Still Active?
Yes. Tissue-level mitochondrial activity persists 8–12 hours despite undetectable plasma concentration. SS-31 binds cardiolipin at the inner mitochondrial membrane, and dissociation kinetics are slow relative to plasma clearance. A study published in Basic Research in Cardiology (Szeto et al., 2011) demonstrated that mitochondrial respiratory function remained protected 8 hours post-dose in cardiac myocytes, long after plasma SS-31 was cleared. The functional endpoint. Cristae preservation, reduced cytochrome c release, maintained ATP synthesis. Depends on membrane-bound peptide, not circulating levels. If your protocol measures oxidative stress markers or apoptotic indices 6–8 hours post-administration and plasma is undetectable, that's expected and doesn't indicate loss of biological effect.
What If I'm Running a Chronic Neurodegeneration Model — Should I Dose Twice Daily to Compensate for the Short Half-Life?
No. Once-daily dosing is sufficient for chronic models and matches what published Alzheimer's and Parkinson's protocols use. The mechanism SS-31 targets. Mitochondrial cristae stability, prevention of membrane permeability transition, maintenance of respiratory chain supercomplexes. Doesn't require continuous peptide presence. A 2016 study in Neurobiology of Disease (Manczak et al.) showed that once-daily subcutaneous SS-31 at 5 mg/kg over 8 weeks reduced amyloid-beta accumulation and improved spatial memory in APP/PS1 transgenic mice, with no additional benefit when dosing increased to twice daily. Chronic mitochondrial protection is cumulative; the structural changes SS-31 induces (cristae integrity, reduced ROS generation) persist between doses. Twice-daily dosing adds logistical complexity without improving outcomes in models where injury accumulates over weeks.
What If I Need Immediate Mitochondrial Protection in an Acute Stroke Model — Does Timing Relative to Half-Life Matter?
Yes. Administer SS-31 as close to the ischemic event as possible, ideally within 15–30 minutes. The short half-life means peak plasma and tissue concentration occur rapidly, but mitochondrial membrane permeabilization during ischemia-reperfusion creates a narrow intervention window. A study in Stroke journal (Cho et al., 2007) found that SS-31 administered 15 minutes before middle cerebral artery occlusion reduced infarct volume by 44%, but delaying administration until 2 hours post-occlusion reduced protection to <20%. The half-life isn't the limiting factor. The pathophysiology is. Mitochondrial outer membrane permeabilization and cytochrome c release occur within 1–3 hours of reperfusion; SS-31 must reach mitochondria before this cascade completes. Bolus IV dosing at 5 mg/kg immediately pre- or post-injury is standard in rodent stroke models.
What If I'm Combining SS-31 With Other Mitochondrial-Targeted Compounds — Does the Half-Life Create Timing Conflicts?
No. SS-31's renal clearance pathway and lack of CYP450 metabolism mean minimal pharmacokinetic interaction with most research peptides. Labs running combination protocols with Thymosin Alpha 1 Peptide for immune-mitochondrial crosstalk studies or Epithalon Peptide for telomere-mitochondrial aging models report no dosing conflicts. The short plasma half-life actually reduces overlap risk. SS-31 clears before most co-administered compounds reach peak concentration. If staggering doses for mechanistic separation, administer SS-31 first (for immediate mitochondrial targeting), then longer-acting peptides 2–4 hours later. The tissue residence time of SS-31 ensures mitochondrial occupancy continues while the second compound distributes.
The Mechanistic Truth About SS-31 Half Life
Here's the honest answer: plasma half-life is the wrong pharmacokinetic parameter to obsess over when designing SS-31 protocols. The 2.5–3 hour figure describes how fast the peptide clears from circulation. It says nothing about how long it remains active at mitochondrial membranes, which is the only residence time that matters for therapeutic endpoints. Researchers who dose SS-31 multiple times daily because
Frequently Asked Questions
How long does SS-31 stay in the bloodstream after injection?
▼
SS-31 has a plasma half-life of approximately 2.5–3 hours in humans, meaning circulating levels drop to half the peak concentration within that timeframe. However, tissue residence time in cardiac and skeletal muscle extends 8–12 hours due to selective binding to cardiolipin at the inner mitochondrial membrane. The peptide clears from plasma via renal filtration and peptidase degradation, but mitochondrial activity persists long after plasma levels become undetectable.
Can I dose SS-31 once daily despite the short half-life?
▼
Yes — once-daily dosing is standard in chronic disease models and matches published protocols for neurodegeneration, metabolic dysfunction, and aging studies. The short plasma half-life does not limit efficacy because SS-31 binds to mitochondrial membranes where it remains active for 8–12 hours, far longer than circulating levels persist. Twice-daily dosing adds logistical complexity without improving outcomes in most chronic models, though acute injury protocols may use multiple doses within the first 24 hours.
What is the cost of SS-31 peptide for a typical research protocol?
▼
Research-grade SS-31 (elamipretide) pricing depends on purity grade, batch size, and synthesis method, with costs typically ranging from several hundred to over a thousand dollars per 10–50 mg depending on supplier and verification level. A chronic 8-week rodent study dosing 20 mice at 5 mg/kg daily requires approximately 150–200 mg total peptide. Labs should budget for independent mass spectrometry verification if using SS-31 in mitochondrial injury models where sequence accuracy determines cardiolipin binding selectivity.
What are the risks of using SS-31 in combination with other mitochondrial peptides?
▼
SS-31 exhibits minimal pharmacokinetic interaction risk due to its renal-dominant clearance and lack of cytochrome P450 metabolism. Combination protocols with peptides like NAD precursors, MOTS-c, or thymosin alpha-1 show no evidence of competitive inhibition or clearance interference in published studies. The primary consideration is mechanistic redundancy — combining multiple mitochondrial-targeted antioxidants may saturate cardiolipin binding sites without additive benefit. Stagger dosing by 2–4 hours if mechanistic separation is required for endpoint interpretation.
How does SS-31 half-life compare to other mitochondrial-targeted peptides?
▼
SS-31’s 2.5–3 hour plasma half-life is shorter than some mitochondrial peptides like MOTS-c (approximately 4–6 hours) but longer than highly polar tripeptides that clear within 30–60 minutes. The critical difference is tissue residence time rather than plasma kinetics — SS-31’s cardiolipin binding produces prolonged mitochondrial membrane occupancy that other peptides lacking the aromatic-cationic motif cannot replicate. MitoQ and SkQ1, alternative mitochondria-targeted antioxidants, show similar plasma clearance but accumulate via different mechanisms (lipophilic cation targeting versus cardiolipin binding).
Does SS-31 require refrigeration because of its short half-life?
▼
No — storage requirements are determined by peptide stability, not plasma half-life. Lyophilized SS-31 should be stored at −20°C before reconstitution to prevent degradation of the aromatic-cationic structure. Once reconstituted with bacteriostatic water, store at 2–8°C and use within 28 days. Temperature excursions above 25°C can degrade the dimethyltyrosine residue that is essential for mitochondrial targeting, rendering the peptide ineffective regardless of how it behaves in circulation.
What happens if I administer SS-31 too late after an ischemic injury?
▼
Delaying SS-31 administration beyond 2 hours post-injury significantly reduces efficacy in acute ischemia-reperfusion models because mitochondrial outer membrane permeabilization and cytochrome c release occur within 1–3 hours of reperfusion. A study in rats (Cho et al., 2007) found infarct size reduction dropped from 44% when SS-31 was given 15 minutes before occlusion to <20% when delayed until 2 hours post-reperfusion. The therapeutic window is narrow not because of the peptide's half-life but because the mitochondrial injury cascade completes rapidly — SS-31 must reach membranes before irreversible permeabilization occurs.
Why do clinical trials use IV infusion if subcutaneous dosing produces similar tissue levels?
▼
Clinical trials frequently use IV infusion for regulatory standardization, precise dose delivery, and immediate peak plasma concentration in acute settings like heart failure decompensation. Subcutaneous administration produces equivalent tissue distribution and mitochondrial accumulation but with a delayed Cmax (30–60 minutes vs 15–30 minutes IV). For chronic outpatient models, subcutaneous is preferred due to convenience and patient compliance. The route choice depends on study design and urgency, not on pharmacokinetic necessity — both routes deliver SS-31 to mitochondria effectively.
Can you measure SS-31 concentration in mitochondria directly to confirm dosing adequacy?
▼
Direct mitochondrial SS-31 measurement requires tissue extraction, mitochondrial isolation, and LC-MS/MS analysis — techniques that are feasible in animal models but not in clinical settings. Surrogate markers include mitochondrial respiration rates (oxygen consumption), cristae integrity via electron microscopy, cytochrome c release into cytosol, and ATP synthesis capacity. Functional endpoints like infarct size, cognitive performance, or exercise tolerance provide indirect evidence of mitochondrial SS-31 activity and are the standard for protocol optimization when direct measurement is impractical.
Is there a dose above which SS-31 half-life or clearance changes non-linearly?
▼
No evidence suggests non-linear pharmacokinetics within the dose ranges used in research (1–10 mg/kg in rodents, 0.25–1 mg/kg in humans). Renal clearance remains the dominant elimination pathway across doses, and cardiolipin binding sites saturate at moderate tissue concentrations without altering systemic clearance. The dose-response curve for efficacy plateaus at 2.5–5 mg/kg in rodents, but this reflects mitochondrial binding capacity limits rather than altered half-life. Escalating dose beyond this range increases cost without proportional benefit.
